Oscar Health Stock News

Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A expense ratio. Barclays' downgrade highlights policy risk, projecting over 100bps MLR pressure and aggressive EPS cuts if subsidies expire.

On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?

In this video, I explain why Oscar Health (OSCR -18.73%) crashed 18% on Wednesday and why I will buy shares. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Growth stocks have been on a tumultuous ride in 2025. The confluence of geopolitical turmoil, high interest rates, the artificial intelligence (AI) superbuild, and valuation concerns has created dramatic volatility.

Oscar generated $328.8 million in Q1 adjusted EBITDA with a 9.8% operating margin, up 110 bps year-over-year. SG&A ratio fell to 15.8%, driven by 40% fixed-cost leverage and 15% tech-driven efficiencies like 98% auto-claims processing. A 5-year DCF with 30% FCF growth and a 5x terminal multiple supports a $61/share fair value, over 3x upside.

The stock market is in an odd place. Tech valuations, from a historical standpoint, look stretched to the breaking point.

Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue from +Oscar and data licensing is compounding faster than insurance premiums, creating a high-margin, SaaS-like earnings stream that legacy insurers can't match. Favorable policy trends and employer...

Oscar Health, Inc. is undervalued despite a recent rally, with strong growth and earnings potential as a tech-driven disruptor in health insurance. The company boasts accelerating revenues, improving profitability, a robust balance sheet, and positive cash flow, supporting further upside. ACA enrollment growth, favorable ICHRA trends, and industry disruption position Oscar for continued success...